HOUSTON – OncoResponse, an immuno-oncology antibody discovery company, has been launched jointly by The University of Texas MD Anderson Cancer Center (MD Anderson) and Theraclone Sciences. Bracewell represented MD Anderson in connection with the closing of a $9.5 million Series A financing in OncoResponse, which financing was co-led by ARCH Venture Partners, Canaan Partners and MD Anderson. William Marsh Rice University and Alexandria Real Estate Equities also participated. OncoResponse is the latest collaborative effort by MD Anderson to further the development of a biotech hub in Houston.
OncoResponse will use Theraclone’s I-STAR™ immune repertoire screening technology to identify therapeutic antibodies against novel targets from immuno-oncology treated patients. MD Anderson will provide access to sample data from patients that have responded well to cancer immunotherapies, along with oncology and translational medicine expertise.
Bracewell attorneys working on this transaction include:
Partner: Janice Z. Davis